

Rabbit Anti-CA125/MUC16 Recombinant [OCA125/2349R]: RM0219, RM0219RTU7

Intended Use: For Research Use Only

Description: Carcinoma antigen 125 (CA125) is a high molecular weight tumor antigen. It is a heavily glycosylated mucin encoded by MUC16 gene. It is expressed on ovarian carcinoma and several epithelial tumors including endometrial carcinoma, cervix carcinoma and clear cell carcinoma of bladder. In addition, CA125 also binds to mesothelin and expressed on mesothelioma. The binding of CA125 to mesothelin may contribute to ovarian cancer metastasize to peritoneum.


Specifications:

Clone: OCA125/2349R
Source: Rabbit
Isotype: IgG
Reactivity: Human
Immunogen: Purified human MUC16 protein
Localization: Membrane, cytoplasm
Formulation: Antibody in PBS pH7.4, containing BSA and $\leq 0.09\%$ sodium azide (NaN₃)
Storage: Store at 2°- 8°C
Applications: IHC
Package:

Description	Catalog No.	Size
CA125/MUC16 Recombinant Concentrated	RM0219	1 ml
CA125/MUC16 Recombinant Prediluted	RM0219RTU7	7 ml

IHC Procedure*:

Positive Control Tissue: Ovarian cancer
Concentrated Dilution: 50-200
Pretreatment: Tris EDTA pH9.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C
Incubation Time and Temp: 30-60 minutes @ RT
Detection: Refer to the detection system manual
* Result should be confirmed by an established diagnostic procedure.



FFPE human endometrial carcinoma stained with anti-CA125 using DAB

References:

1. Megakaryocytic potentiating factor and mature mesothelin stimulate the growth of a lung cancer cell line in the peritoneal cavity of mice. Zhang J, et al. PLoS One 9:e104388, 2014.
2. Expression of cathepsin-D, CA125 and epidermal growth factor receptor in imprint smears of ovarian carcinoma. Athanassiadou P, et al. Gynecol Obstet Invest 43:125-30, 1997.
3. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site. Brown RW, et al. Am J Clin Pathol 107:12-9, 1997.
4. Tissue CA 125 and CA 19-9 in malignant, mixed mesodermal tumors of the uterus. Podczaski E, et al. Gynecol Oncol 49:56-60, 1993.

Doc. 100-RM0219
Rev. A